Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Endometrial cancer, drawn from the whole corpus: 106 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
p53-abnormal disease behaves like serous ovarian.
Obesity-driven incidence rising.
Equity: more p53-abnormal tumours and later diagnosis mean Black women in the US have nearly twice the mortality of white women; incidence and mortality are rising overall with obesity.
p53-abnormal and carcinosarcoma histologies still relapse frequently despite chemoradiation; no subtype-specific therapy is approved beyond HER2.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Immunotherapy benefit in pMMR disease is modest and biomarkers to select pMMR responders are lacking.
Optimal adjuvant strategy by molecular class is unproven prospectively until RAINBO and PORTEC-4a report.
Whether radiation adds to chemotherapy in stage III disease remains unresolved (PORTEC-3 vs GOG-258).
Fertility-sparing therapy has a 30% relapse rate and no reliable predictor of response.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Lenvatinib-pembrolizumab toxicity forces dose reductions in two-thirds of patients.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 39 changes by month →When this page itself was last checked or edited.
XPORT-EC-042 misses primary endpoint; endometrial development deprioritised
Primary PFS endpoint not met; mPFS 12.
Post-hoc TP53-wild-type subgroup hypothesis not confirmed.
Breakthrough Therapy designation, advanced endometrial cancer after PD-(L)1 and platinum
ORR 55.